Mrs. Ashley Nichole Frizzell, LCSW, CADC Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 310 E Howard St, Pontiac, IL 61764 Phone: 815-791-2955 |
Patricia Mortensen Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 310 E Torrance Ave, Pontiac, IL 61764 Phone: 815-844-6109 Fax: 815-844-3561 |
Judy Ripsch Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 325 E Timber St # A, Pontiac, IL 61764 Phone: 815-844-2610 Fax: 815-844-2652 |
Jessica J Siwak, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 920 W Custer Ave, Pontiac, IL 61764 Phone: 815-844-6109 Fax: 815-844-3561 |
Ms. Ann Christine Crumpler, MSSW LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 2500 W Reynolds St, Suite 207 St. James Hospital, Psychology Specialists, Pontiac, IL 61764 Phone: 815-579-9002 Fax: 309-588-4115 |
Carrie Hamilton, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 920 W Custer Ave, Pontiac, IL 61764 Phone: 815-844-6109 Fax: 815-844-3561 |
Jayme Evelyn Bradshaw, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 735 S Locust St, Pontiac, IL 61764 Phone: 815-690-7170 |
News Archive
The mortality of alcohol dependent patients in general hospitals is many times higher than that of patients without alcohol dependency.
Scientists from the Florida campus of The Scripps Research Institute have identified a protein that impairs the development and maintenance of lymphoma (cancer of the lymph nodes), but is repressed during the initial stages of the disease, allowing for rapid tumor growth.
Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Sumatriptan Succinate Tablets, 25 mg (base), 50 mg (base) and 100 mg (base). This product is manufactured in Mylan's Morgantown, W.Va. facility.
iCo Therapeutics Inc. today announced that the company has entered into a research collaboration agreement with JDRF, the worldwide leader for research to cure, treat, and prevent type 1 diabetes (T1D), to support the previously announced Phase 2 investigator sponsored clinical trial investigating iCo-007 in Diabetic Macular Edema.
It currently takes 5 years on average to diagnose a child with a rare genetic disease, so he or she can receive the most appropriate care. This is set to change with an agreement facilitated by Northern Health Science Alliance (NHSA) between Congenica and 5 of its member hospitals, which will see them adopt the company's world leading Sapientia™ technology.
› Verified 9 days ago